Revista nº 792

95 / 64

95 Elena Beatriz Bermúdez Bejarano
Patología odontológica y bifosfonatos en la prática clínica diaria
* RAR: Raspado Alisado Radicular
* Riesgo de ONM:
Bifosfonatos orales à bajo riesgo ONM en procedimientos
dentales.
Bifosfonatos intravenosos à alto riesgo ONM en procedi-
mientos dentales.
CONCLUSIONES
En un paciente en terapia con bifosfonatos es fundamental
la prevención como arma, siendo básica una exhaustiva historia
clínica y un adecuado conocimiento de este tipo de fármacos,
para evitar así, futuras complicaciones.
REFERENCIAS
1. Licata AA. Discovery, Clinical Development and
Therapeutic uses of the Bisphosphonates. Annals of
Pharmacotherapy. Abr 2005; 39 (4): 668-677.
2. Matthew T. Drake, MD, PhD, Bart L. Clarke, MD, and
Sundeep Khosla, MD. Bisphosphonates: Mechanism
of Action and Role in Clinical Practice. Mayo Clin Proc.
September 2008; 83(9): 1032–1045.
3. Jaimes, M.; Chaves Netto, H. D. M.; Olate, S.; Chaves,
M. M. G. A. & Barbosa, A. J. R. Biphosphonate and Jans
osteonecrosis. Considerations about of treatment. Int. J.
Morphol. 2008 ; 26(3):681-688.
4. Migliorati, C.; Casiglia, J.; Epstein, J.; Jacobsen, P.; Siegel,
M; Woo, Sook-Bin. Managing the care of patients with
bisphosphonateassociated osteonecrosis An American
Academy of Oral Medicine position paper. JADA .
December 2005; Vol. 136.
5. Khosla, S.; Burr, D.; Cauley, J. Bisphosphonate-Associated
Osteonecrosis of the Jaw: Report of a Task Force of the
American Society for Bone and Mineral Research. J Bone
Miner Res. 2007; 22:1479–1491.
6. Bagán José.V. Blade, J.; Cozar, JM. Recommendations
for the prevention, diagnosis, and treatment of
osteonecrosis of the jaw (ONJ) in cancer patients treated
with bisphosphonates. Med Oral Patol Oral Cir Bucal.
2007; 12:E336-40.
7. Junquera, LM.; Acero, J.; Burgueño, M. Diagnóstico,
prevención y tratamiento de la osteonecrosis de los
maxilares por bisfosfonatos. Recomendaciones de
la sociedad española de cirugía oral y maxilofacial
(SECOM). Cient Dent. 2008; 5;3:229-237
8. Yamashita, J.; Mc Cauley, L.; Van Poznak, C. Updates on
Osteonecrosis of the Jaw. Curr Opin Support Palliat Care.
September 2010 ; 4(3): 200–206.
9. Ensaldo, E; Prado, N.;Prado, J. Manejo estomatológico
del paciente en terapia con bifosfonatos .Una Guía de
Manejo para el profesional de la salud. Revista ADM.
2011/VOL .LXVIII . No.1. pp. 8-16
10. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of
the jaws associated with cancer chemotherapy.J Oral
Maxillofac Surg. 2003; 61:1104-7.
11. Marx RE. Pamidronate (Aredia) and zolendronate
(Zometa) induced avascular necrosis of the jaws: a
growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
12. Sook-Bin Woo.; Kalmar, J.; Hellstein, J. Systematic
Review: Bisphosphonates and Osteonecrosis of the
Jaws. Annals of Internal Medicine. 2006 ; Volume 144
; Number 10
13. Diniz-Freitas, M.; López-Cedrún, JL.; Fernández-
Sanromán, J. Oral bisphosphonate-related osteonecrosis
of the jaws: Clinical characteristics of a series of 20 cases
in Spain. Med Oral Patol Oral Cir Bucal. Sep 2012; 1;17
(5):e751-8.
14. Sosa Henríquez M. Gómez de Tejada Romero MJ.; Bagán
Sebastián, JV. Osteonecrosis de los
de consenso. Rev Osteoporos Metab Miner 2009;
1;1:41-51.
15. .Ruggiero, S.; Mehrota, B.; Rosenberg, T.; Engroff, S.
Osteonecrosis of the Jaws Associated With the Use of
Bisphosphonates: A Review of 63 Cases. J Oral Maxillofac
Surg, 2004; 62:527-534.
16. Ruggiero, S.; Fanatasia, J.; Carlson, E. Bisphosphonate-
related osteonecrosis of the jaw: background and
guidelines for diagnosis, staging and Management.
OOOOE. 2006. Vol. 102 No. 4.
17. Ruggiero, S. American Association of Oral and
Maxillofacial Surgeons Position Paper on Bisphosphonate-
Related Osteonecrosis of the Jaws—2009 Update. J Oral
Maxillofac Surg. 2009; 67:2-12, 2009, Suppl 1
18. Flichy-Fernández, AJ. ; Alegre-Domingo, T.; González-
Lemonnier, S. Study of serum CTX in 50 oral surgical
patients treated with oral bisphosphonates. Med Oral
Patol Oral Cir Bucal. May 2012; 1;17(3):e367-70.
19. American Association Endodontics. Position Statement.
Endodontic Implications of Bisphosphonate-Associated
Osteonecrosis of the Jaws. American Association of
Endodontists. 2006; 211 E.
20. Edwards, B.; Hellstein, J.; Jacobsen, P.. Updated
recommendations for managing the care of patients
receiving oral bisphosphonate therapy An advisory
statement from the American Dental Association Council
on Scientific Affairs. JADA 2008 ;139(12):1674-1677.
21. Jayalakshmi K.; Ravikumar, H.; Archana, P.
Bisphosphonates in Oral Diseases: Updates of its
implications in Dental Management. JIOH 2012; Volume
4; Issue 2.
22. Marunick, M.; Gordon, S. Prosthodontic treatment
during active osteonecrosis related to radiation and
bisphosphonate therapy: A clinical report. J Prosthet
Dent 2006; 96:7-12.
23. Iglesias-Linares, A.; Yáñez-Vico, RM.; Solano- Reina, E.
Influence of bisphosphonates in orthodontic therapy:
Systematic review. Journal of Dentistry. 2010 ; 603-611.
24. Giannobile. Host-Response Therapeutics for Periodontal
Diseases. J Periodontol. August 2008 ; 79(8 Suppl):
1592–1600.
25. Mawardi, h.; Kjiya, M.; Gino, G. A Role of Oral Bacteria in
Bisphosphonate-induced Osteonecrosis of the Jaw. J Dent
Res. 2011; 90(11):1339-1345.
26. Flichy-Fernández, AJ.; Balanguer- Martínez, J.; Peñarrocha-
Diago, M. Bisphosphonates and dental
problems. Med Oral Patol Oral Cir Bucal. Jul 2009; 1;14
(7):E355-60.